M&A

Gujarat Themis to buy Sanofi TB brands for €158M

What's the deal? Gujarat Themis Biosyn (GTBL)Dealroom has a profile for this one. Try Dealroom → has agreed to acquire 13 Sanofi tuberculosis and anti-infective brands for about €158 million. The portfolio generated roughly €62 million in revenue in FY 2025 across more than 55 countries.

What's included? GTBL gains the brands, marketing authorisations, regulatory dossiers, and inventory — but no factories, no manufacturing capital expenditure, and no employee transfers. Key molecules include Levofloxacin, Rifampicin, and Rifapentine, which the company classifies as World Health Organization essential and EU critical medicines.

What's the endgame? The deal pushes GTBL beyond its current intermediates and active pharmaceutical ingredients (APIs) business into market-facing, finished-dose products. It opens regulated markets across Europe, the Middle East, and Africa, with about 70% of portfolio revenue coming through retail.

The numbers: GTBL reported a Q2 net loss following its separate MicroBiopharm acquisition. The €62 million portfolio figure is Sanofi revenue, not yet consolidated into GTBL's own accounts.

What could go wrong? GTBL will fund the purchase through a mix of debt and equity but has not disclosed the split, financing terms, or a completion date. Its credit rating was placed on negative watch over the acquisition plans, and the deal runs alongside the pending MicroBiopharm purchase in Japan — making financing and integration central tests.

The signal: The purchase reflects a broader Indian pharma push to buy established brands and move beyond generics and manufacturing. For GTBL, the scale raises the stakes: success now hinges on regulatory clearance, the debt-equity burden, and whether it can deliver the promised earnings.

Read more: multibagg.ai

Image credit: Generated with Gemini

More top stories